Prospective prophylaxis study with 3,532 healthcare workers, 2,199 receiving two-dose ivermectin prophylaxis, showing adjusted relative risk of confirmed COVID-19 with treatment 0.17 [0.12-0.23] p
186 patients took only the first dose, and no significant difference was observed for this group. The same group published an earlier small study with 115 ivermectin patients.
Behera et al., 2/15/2021, prospective, India, South Asia, preprint, 13 authors, dosage 300μg/kg days 1, 4.
risk of COVID-19 case, 83.0% lower, RR 0.17, p < 0.001, treatment 2199, control 1147, two doses.
risk of COVID-19 case, 4.0% higher, RR 1.04, p = 0.85, treatment 186, control 1147, patients only receiving the first dose.
Effect extraction follows pre-specified rules prioritizing more serious
outcomes. For an individual study the most serious outcome may have a smaller
number of events and lower statistical signficance, however this provides the
strongest evidence for the most serious outcomes when combining the results of